Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer

被引:20
作者
Yu, Hui Ming [1 ]
Liu, Yun Fang [2 ]
Yu, Jin Ming [3 ]
Liu, Jie [4 ]
Zhao, Yuxia [1 ]
Hou, Ming [1 ]
机构
[1] Shandong Univ, Sch Med, Dept Oncol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Dept Med Diag, Jinan 250012, Shandong, Peoples R China
[3] Shandong Univ, Shandong Tumor Hosp, Dept Radiat Oncol, Jinan 250012, Shandong, Peoples R China
[4] Shandong Prov Hosp, Dept Radiat Oncol, Jinan, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung carcinoma; involved-field radiation therapy; intensity-modulated radiotherapy; clinical trial;
D O I
10.1016/j.radonc.2008.01.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all lung cancers, especially in patients 70 years old or more. In this study, we investigated the efficacy and safety of involved-field radiotherapy (IFRT) for patients 70 years old or more with early stage NSCLC. Patients and methods: We conducted a multicenter prospective study in elderly patients with NSCLC treated with intensity-modulated radiotherapy (IMRT). From January 1999 to December 2001, 80 patients with medically inoperable or refused surgery early stage (I/II) NSCLC were eligible for toxicity and treatment response analysis. IMRT plans were designed to deliver 66.6 Gy to involved-field that included only the primary tumor and clinically enlarged lymph nodes using six equidistant coplanar 6-MV beams. Elective nodal failure (ENF) was defined as a recurrence in an initially uninvolved lymph node in the absence of local failure. Results: The objective response rate of all patients was 88.6% with a median overall survival (OS) time of 38 months and the 1-, 2- and 5-year OS rates and local progression-free survival (LPFS) rates were 65.8%, 55.7%, 25.3% and 84.8%, 59.5%, 34.2%, respectively. The medians OS time for patients with gross tumor volume (GTV) > 100.8 cm(3) and GTV <= 100.8 cm(3) were 13 and 50 months, respectively (p = 0.0001). Only 29 patients (36.7%) with ENF were identified, with a median time to treatment failure of 55 months (range, 49-61 months) after treatment. There were no treatment-related deaths or grade 4 toxicity. Grade 3 toxicities were esophagitis (1.3%), radiation pneumonitis (3.8%) and hematological effects (2.5%). Conclusions: This study indicated that IFRT using IMRT did not cause a significant amount of failure in lymph node regions not included in the tumor volume and improved outcomes in elderly patients. Therefore, IFRT is an acceptable technique in the treatment of elderly inoperable NSCLC. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 36 条
[1]   Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy [J].
Belderbos, Jose S. A. ;
Heemsbergen, Wilma D. ;
De Jaeger, Katrien ;
Baas, Paul ;
Lebesque, Joos V. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :126-134
[2]   A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-smatt cell lung cancer [J].
Bral, Samuel ;
Van Parijs, Hitde ;
Soete, Guy ;
Linthout, Nadine ;
Van Moorter, Lutgard ;
Verellen, Dirk ;
Storme, Guy .
RADIOTHERAPY AND ONCOLOGY, 2007, 84 (03) :252-256
[3]   Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes [J].
Chapet, Olivier ;
Khodri, Mustapha ;
Jalade, Patrice ;
N'guyen, Daniel ;
Flandin, Isabelle ;
D'hombres, Anne ;
Romestaing, Pascale ;
Mornex, Francoise .
RADIOTHERAPY AND ONCOLOGY, 2006, 80 (03) :333-340
[4]   Involved-field radiotherapy alone for early-stage non-small-cell lung cancer [J].
Cheung, PCF ;
Mackillop, WJ ;
Dixon, P ;
Brundage, MD ;
Youssef, YM ;
Zhou, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :703-710
[5]  
DERUYSSCHER D, 2007, INT J RAD ONCOL 1123
[6]   Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy [J].
Fang, L. Christine ;
Komaki, Ritsuko ;
Allen, Pamela ;
Guerrero, Thomas ;
Mohan, Radhe ;
Cox, James D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :108-116
[7]   Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer [J].
Faria, Sergio L. ;
Souhami, Luis ;
Portelance, Lorraine ;
Duclos, Marie ;
Vuong, Te ;
Small, David ;
Freeman, Carolyn R. .
RADIATION ONCOLOGY, 2006, 1 (1)
[8]   The curative treatment by radiation therapy alone of Stage I non-small cell lung cancer in a geriatric population [J].
Gauden, SJ ;
Tripcony, L .
LUNG CANCER, 2001, 32 (01) :71-79
[9]   Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation [J].
Grills, IS ;
Yan, D ;
Martinez, AA ;
Vicini, FA ;
Wong, JW ;
Kestin, LL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03) :875-890
[10]   High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer [J].
Hayakawa, K ;
Mitsuhashi, N ;
Katano, S ;
Saito, Y ;
Nakayama, Y ;
Sakurai, H ;
Akimoto, T ;
Hasegawa, M ;
Yamakawa, M ;
Niibe, H .
LUNG CANCER, 2001, 32 (01) :81-88